RECEIVED CENTRAL FAX CENTER

MAR 1 4 2005

PATENT

Ø 001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(MBHB Case No. 02-760-A)

in the Ap	plication of:)	
I	Fobian, et al.)	Before the Examiner: Shailendra Kumar
Serial No	o. 10/657,567)	Art Unit: 1621
Filed: S	September 8, 2003)	
	l, 3-Diamino-2-Hydroxypropane Prodrug Derivatives)))	

FACSIMILE TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attn:

Examiner Kumar

Fax 703-872-9306

No. of Pages: 3

Including this Transmittal Letter

Şir:

In regard to the above identified application:

- 1. We are transmitting herewith the attached:
 - a. Response to the Restriction Requirement Mailed February 14, 2005
- No fees are due at the present time.
- Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490.
- 4. CERTIFICATE OF TRANSMISSION UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being facsimile transmitted to the Patent and Trademark Office (Fax No. 703-872-9306) on this 14th day of March, 2005.

Bradley W. Crawfo Reg. No. 50,494

McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive Chicago, Illinois 60606 Telephone: 312-913-0001 Facsimile: 312-913-0002

CERTIFICATE OF MAILING

MAR 1 4 2005

RECEIVED

CENTRAL FAX CENTER

3-14-as Bradling Total

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Case No. 02-760-A

In re Application of:)		٥
Fobian, et al.)		
)	Before the Shailendra	
Serial No.: 10/657,567)		
Filed: September 8, 2003	}	Art Unit:	1621
For: 1,3-Diamino-2-Hydroxypropane Prodrug derivatives)		
) }		
	}		•

RESPONSE TO THE RESTRICTION REQUIREMENT MAILED FEBRUARY 14, 2005

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Restriction Requirement mailed February 14, 2005, the Applicants elect the invention of Group II, i.e., the heterocyclic compounds and compositions for prosecution. The Applicants further select compound 9, from page 179, which has the following structure:

Applicants further note that the name of compound 9, on page 179 of the application as filed is incorrect. The proper name (generated using ChemDraw Ultra v. 8.03) is (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-(1-(3-ethynylphenyl)cyclopropylamino)butan-2-yl 3-(dipropylcarbamoyl)-5-(oxazol-2-yl)benzoate.

CONCLUSION

The Applicants invite the Examiner to contact the Applicants' undersigned representative at (312) 913-2114 if the Examiner believes that this would expedite prosecution of this application.

Respectfully submitted,

March 14, 2005

Bradley W. Crawford Reg. No. 50,494